---
title: "Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284637615.md"
description: "The trial was assessed by the Independent Data Monitoring Committee (IDMC) and found to be unlikely to achieve the primary endpoint."
datetime: "2026-04-29T20:07:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284637615.md)
  - [en](https://longbridge.com/en/news/284637615.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284637615.md)
---

# Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis

The trial was assessed by the Independent Data Monitoring Committee (IDMC) and found to be unlikely to achieve the primary endpoint.

### Related Stocks

- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [ALEC.US](https://longbridge.com/en/quote/ALEC.US.md)

## Related News & Research

- [J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)](https://longbridge.com/en/news/293769510.md)
- [REG - GSK PLC - Hansoh positive 2nd Phase III results for Riz-Rez](https://longbridge.com/en/news/294046906.md)
- [REG - GSK PLC - Director/PDMR Shareholding](https://longbridge.com/en/news/293770663.md)
- [Citigroup Reiterates "Neutral" Rating for GSK (NYSE:GSK)](https://longbridge.com/en/news/293754519.md)
- [GSK launches 3-year cost-savings program to simplify organization, fund R&D push](https://longbridge.com/en/news/294054848.md)